Detail akcie Tevogen Bio Rg online

Business Summary: Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tevogen Bio Holdings Inc revenues was not reported. Net loss applicable to common stockholders increased from $865K to $22M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 47% to $21.5M. Basic Earnings per Share excluding Extraordinary Items totaled to -$0.13.